Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06938347 · ClinicalTrials.gov registry record · Phase 3
Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt
A Phase 3 study of Right-To-Left Shunt, sponsored by Agitated Solutions.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 5
- Study locations
NCT06938347 is a Phase 3 study of Right-To-Left Shunt that is actively recruiting participants, run by Agitated Solutions. The registered enrollment target is 300 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT06938347, a Phase 3 study of Right-To-Left Shunt, is actively recruiting participants, sponsored by Agitated Solutions.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a phase 3, multicenter, open-label, blinded, crossover trial in which each participant will undergo a randomized sequence of ASI-02 and agitated saline standard of care (SoC) via a saline contrast transthoracic echocardiogram (TTE) study.
Conditions Studied
Interventions
- DRUG Agitated Saline SoC
- DRUG ASI-02
Study Locations (5)
Illinois
- Northwestern University - Chicago
Minnesota
- Mayo Clinic - Rochester
Mississippi
- Jackson Heart Clinic - Jackson
New York
- NYU Langone Health - New York
Other
- Toronto General - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-11-05 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06938347
The ClinicalTrials.gov registry entry for NCT06938347 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agitated Solutions, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Right-To-Left Shunt appearing as the primary indexed condition, and to 2 interventions - of which Agitated Saline SoC is the first listed.
NCT06938347 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Minnesota, Mississippi.
Frequently Asked Questions
What is clinical trial NCT06938347 about?
NCT06938347 is a clinical study titled "Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt". This is a phase 3, multicenter, open-label, blinded, crossover trial in which each participant will undergo a randomized sequence of ASI-02 and agitated saline standard of care (SoC) via a saline contrast transthoracic echocardiogram (TTE) study.
What is the current status of trial NCT06938347?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2025-11-05. Estimated completion is 2026-06.
What conditions does trial NCT06938347 study?
This clinical trial studies the following conditions: Right-To-Left Shunt.
What interventions are being tested in trial NCT06938347?
The interventions under investigation include: Agitated Saline SoC (DRUG), ASI-02 (DRUG).
Who is sponsoring clinical trial NCT06938347?
This trial is sponsored by Agitated Solutions, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06938347 being conducted?
This trial has 5 study locations across Illinois, Minnesota, Mississippi, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.